Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy

International Journal of Dermatology

Volumn 49, Issue 12, 2010, Pages 1445-1449

  Arenbergerova, Monika ^a   Gkalpakiotis, Spyridon ^a   Arenberger, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; MALE; PSORIASIS VULGARIS; SUBFEBRILIA; SUPPURATIVE HIDRADENITIS; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; OBESITY; RECURRENCE; SMOKING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649405959     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04638.x     Document Type: Article

References (22)

1. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998.
2. Jansen T, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurtiva). J Eur Acad Dermatol Venereol 2001; 15: 532-540.
3. Kagan RJ, Yakuboff KP, Warden GD. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery 2005; 138: 734-740.
4. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumor necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 159: 761-763.
5. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-729.
6. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572.
7. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
8. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumor necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
9. Sotiriou E, Apalla Z, Vakirlis E, et al. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19: 180-181.
10. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-1112.
11. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol 2006; 55: 163-164.
12. Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009; 145: 580-584.
13. Harde V, Mrowietz U. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J Dtsch Dermatol Ges 2009; 7: 139-141.
14. Yamauchi PA, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009; 8: 181-183.
15. Kloth LC, Feedar JA. Acceleration of wound healing with high voltage, monophasic, pulsed current. Phys Ther 1988; 68: 503-508.
16. Panteleyev AA, Bickers DR. Dioxin-induced chloracne-reconstructing the cellular and molecular mechanisms of a classic environmental disease. Exp Dermatol 2006; 15: 705-730.
17. Kasai A, Hiramatsu N, Hayakawa K, et al. High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 2006; 66: 7143-7150.
18. Jemec GBE, Wendelboe P. A randomized trial of topical clindamycin vs. systemic tetracycline in hidradenitis suppurativa. J Am Acad Dermatol 1998; 39: 971-974.
19. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006; 83: 526-535.
20. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 154: 1074-1108.
21. Poulin Y. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept. J Cutan Med Surg 2009; 13: 221-225.
22. Lozeron P, Denier C, Lacroix C, Adams D. Long-term cause of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-497.